Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056601 · ClinicalTrials.gov registry record · Phase 2
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01056601 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 7 participants.
The verdict
NCT01056601, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth. Studies have shown that panobinostat (LH589) causes a wide range of effect on endothelial cells that lead to inhibition of tumor angiogenesis (a fundamental step in the transition of tumors from a dormant state to a malignant one). Bortezomib triggers cell death in pancreatic cancer cells but the mechanism is not well defined but has been determined to be cytostatic. Combining these two drugs may work together in the treatment of pancreatic cancer.
Interventions
- DRUG Bortezomib
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01056601
The ClinicalTrials.gov registry entry for NCT01056601 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bortezomib is the first listed.
NCT01056601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01056601 about?
NCT01056601 is a clinical study titled "Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy". Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth. Studies have shown that panobinostat (LH589) causes a wide range of effect on endothelial cells that lead to inhibition of t...
What is the current status of trial NCT01056601?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2010-09. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01056601?
The interventions under investigation include: Bortezomib (DRUG), Panobinostat (DRUG).
Who is sponsoring clinical trial NCT01056601?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.